Literature DB >> 10644791

Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis.

A Komiyama1, H Arai, M Kijima, K Hirayama.   

Abstract

Three patients with generalised myasthenia gravis and three with ocular myasthenia gravis received two to five courses of high dose intravenous methylprednisolone because of the failure of standard immunomodulating therapies. Changes in myasthenic signs were assessed using a four step system for grading muscle weakness and fatiguability in 10 test items. Although a brief and modest amelioration was found from day 1 to day 2 after the initial infusion in two patients with generalised myasthenia gravis, all three experienced a prolonged phase of worsening followed by improvement before the next course. Conversely, for two of the patients with ocular myasthenia gravis, a transient but dramatic improvement of ptosis and ocular immobility was noted from 90 minutes to 5 hours after initiating the first infusion, followed by mild or no exacerbation. This 3 hour improvement may be related not only to possible differences in the neuromuscular junction, but also to corticosteroids unmasking the central adaptation for the peripheral ocular muscle weakness by increasing the acetylcholine release.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644791      PMCID: PMC1736793          DOI: 10.1136/jnnp.68.2.214

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

2.  Eyelid ptosis enhanced after steroid pulse therapy in ocular myasthenia gravis: a case report.

Authors:  Haruo Nishijima; Tatsuya Ueno; Chieko Suzuki; Masayuki Baba; Masahiko Tomiyama
Journal:  Neurol Sci       Date:  2015-01-28       Impact factor: 3.307

Review 3.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

4.  Ocular Myasthenia Gravis.

Authors:  Neil C Porter; Brian C Salter
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

5.  Quality of life in purely ocular myasthenia in Japan.

Authors:  Shigeaki Suzuki; Hiroyuki Murai; Tomihiro Imai; Yuriko Nagane; Masayuki Masuda; Emiko Tsuda; Shingo Konno; Satoru Oji; Shunya Nakane; Masakatsu Motomura; Norihiro Suzuki; Kimiaki Utsugisawa
Journal:  BMC Neurol       Date:  2014-07-05       Impact factor: 2.474

Review 6.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.